Metris Therapeutics Ltd.
http://www.metris.co.uk
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Metris Therapeutics Ltd.
Deals Shaping the Medical Industry (9/06)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Start-Up Previews (10/00)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Cancer Diagnostics, features profiles of Amepersand Medical Corp., Amplistar Inc., Cell Works Inc and Cogs LLC. Plus these selected Start-ups across Health Care: Metris Therapeutics Ltd., Cardeon Corp., LabDat Inc. and Sutura Inc.
Metris Therapeutics Ltd.
Existing drug therapies for endometriosis, including drugs that block estrogen and GnRH agonists bear troubling side effects. Metris Therapeutics hopes to avoid these by taking a different path to the disease. The company's founders were among the first to identfiy increased levels of vascular endothelial growth factor (VEGF) in the peritoneal fluid of women with endometriosis. Metris has therfore set out to develop a product to block VEGF's action.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice